{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'investigators distinguish irAEs from non-immune AEs. These case definitions pertain to the more', 'commonly reported irAEs associated with PD-1 inhibition (Weber 2015) (Naidoo 2015), and is', 'not exhaustive of all possible irAEs. Clinical presentations of less common irAEs, including', 'neurologic, musculoskeletal, cardiac, renal, and ocular events (Zimmer 2016) (Hofmann 2016),', 'should be reviewed in patients with concerning presentations.', 'The case definitions below have not been validated, and are intended only as guidance for', \"investigators to help distinguish irAEs from non-immune AEs. Investigators' clinical judgment\", 'may include other factors when determining immune-relatedness. The case definitions for irAEs', 'may evolve as clinical experience increases with cemiplimab and other antibodies targeting the', 'PD-1/PD-L1 axis.', 'a.', 'Immune-related rash: Skin examination demonstrates a rash that is usually', 'maculopapular, but other presentations may occur, including papulopustular, follicular, or', 'urticarial dermatitis. Consider dermatologic consultation and biopsy for atypical', 'presentations. Exclude other cause such as virally-induced rash or contact dermatitis.', 'b. Immune-related diarrhea/colitis: These events are on a continuum, with diarrhea defined', 'as increased stool frequency, and colitis involves abdominal pain and/or radiologic evidence', 'of colonic inflammation (Naidoo 2015). Onset at 4 to 6 weeks is common (Weber 2015).', 'A CT scan usually demonstrates diffuse colitis (Tirumani 2015). Exclude Clostridium', 'difficile or other infectious etiologies and exclude laxative misuse.', 'c.', 'Immune-related hepatitis: Laboratory studies are notable for elevated ALT and/or AST', 'that is usually asymptomatic. Viral or other drug-induced hepatitis is excluded. Exclude', 'alcohol-related liver toxicity. If clinically appropriate, consider radiologic imaging to', 'exclude malignant causes. If clinically appropriate, exclude worsening of underlying', 'cirrhosis.', 'd. Immune-related hypothyroidism: Laboratory studies are notable for elevated TSH', 'associated with low serum free thyroxine (free T4). If elevated TSH is detected, it is', 'recommended that free T4 level also be tested. Elevated TSH with low free T4 establishes', 'the diagnosis of hypothyroidism. Hypothyroidism may be asymptomatic or associated with', 'symptoms such as fatigue, constipation, cold intolerance, dry skin, weight gain, and/or', 'bradycardia. Exclude other causes of hypothyroidism, such as prior radiation therapy to the', 'neck. In patients with prior history of hypothyroidism, exclude noncompliance with thyroid', 'replacement medication.', 'e.', 'Immune-related hyperthyroidism: Hyperthyroidism should be managed with standard', 'antithyroid pharmacotherapy, and consultation with an endocrinologist is recommended.', 'f.', 'Immune-related pneumonitis: Pneumonitis, defined as inflammation of the lung', 'parenchyma, may present as shortness of breath, cough, fever, and/or chest pain. Median', 'time from start of anti-PD-1 therapy to onset of pneumonitis is 2.6 months (Nishino 2016),', 'but delayed onset of pneumonitis has been reported. The most common radiologic pattern', 'on CT chest has been described as cryptogenic organizing pneumonia, but other', 'radiographic patterns may occur (Nishino 2016). If performed, biopsy may demonstrate', 'lymphocyte-predominant interstitial pneumonitis with areas of organizing pneumonia', '(Nishino 2016). Exclude infectious causes of pneumonitis.', 'Adverse events that meet the criteria above should be entered using the appropriate terms', '(see Appendix 3 for terms corresponding to common potential irAEs), and attributing them as', 'related to cemiplimab. Such related events will be assumed to be irAEs in the database (unless', 'Regeneron Pharmaceuticals, Inc.', 'Page 75 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'medical review of data raises questions regarding the attribution and are queried). If AEs', 'corresponding to the common terms are attributed as NOT related to (cemiplimab), additional', 'information should be provided substantiating an alternative attribution (eg, infectious diarrhea).', 'If not provided at the outset, this information may be requested by immediate edit checks or in', 'subsequent queries.', '8.3.3.', 'Resumption of Cemiplimab After Treatment Hold, or Discontinuation', 'Resumption of cemiplimab after resolution of adverse event to grade 1 (or baseline) is allowed', 'at the discretion of the investigator in accordance with the toxicity management guidelines in this', 'protocol if resumption of treatment is thought to be in best interest of the patient. Treatment after', 'an AE may resume, at the discretion of the investigator, if the AE is felt to be manageable through', 'supportive/medical therapy (eg, grade 3 hypertension that can be controlled with the addition of a', 'second anti-hypertensive agent). However, cemiplimab treatment resumption is not allowed in the', 'following circumstances:', 'Patients with events that require cemiplimab to be permanently discontinued or held', 'for more than 84 days from last scheduled dose', 'Patients with >grade 2 uveitis. Patients with grade 2 uveitis will generally be', 'discontinued from cemiplimab treatment, unless there is resolution to grade 1 AND', 'approval from the medical monitor at the sponsor prior to resumption of treatment.', 'Patients who permanently discontinue from study drug and who do not withdraw from the study', 'should continue follow-up in the study without additional treatment until PD, completion of all', 'study assessments, or closure of the study (Section 6.3). After PD, all patients should be followed', 'for survival.', '8.4.', 'Dose Modification and Study Treatment Discontinuation Rules for', \"Investigator's Choice Chemotherapy\", 'Adverse events are to be reported according to the NCI-CTCAE version 4.03. Dose adjustments', 'at the start of a subsequent cycle should be based on nadir observed hematologic counts or', 'maximum nonhematologic toxicity from the preceding cycle of therapy. Treatment may be', 'delayed to allow sufficient time for recovery. Upon recovery, patients should be retreated using', 'guidelines in the following subsections. The general approach regarding missed doses of IC', 'chemotherapy (eg, due to AEs) is \"time marches on.\" Missed doses of IC chemotherapy will not', 'be made up, unless 3 business days from the scheduled date.', 'The following section provides toxicity management guidelines for selected AEs that are', 'characteristic for the IC agents, pemetrexed, topotecan, irinotecan, gemcitabine, and', 'vinorelbine. For other chemotherapy-related AEs that are not specifically addressed in the', 'following sections, the general approach for > grade 3 chemotherapy treatment-related AEs is to', 'hold chemotherapy until resolution of the event to grade 1 or baseline, and to reduce by one dose', 'level on resumption of treatment.', '8.4.1.', 'Pemetrexed Dose Modifications', 'The dose reduction guidelines for hematologic toxicity are in Table 7.', 'Regeneron Pharmaceuticals, Inc.', 'Page 76 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}